Vietnam is rapidly strengthening its position as an emerging destination for clinical research and pharmaceutical development, creating significant opportunities for contract research organizations (CROs). As global pharmaceutical, biotechnology and medical device companies continue to outsource research and clinical development, Vietnam is becoming an increasingly attractive location for conducting clinical trials, regulatory studies and real-world evidence programmes.
Although there is currently no dedicated published market valuation for Vietnam's CRO services sector, industry analysis indicates the market is worth an estimated US$240–300 million in 2025 and could reach US$430–550 million by 2030. This expansion reflects Vietnam's growing pharmaceutical manufacturing base, improving regulatory environment, expanding healthcare infrastructure and increasing participation in multinational clinical research.
Contract Research Organizations provide outsourced services that support the development of pharmaceuticals, biologics and medical devices throughout the product lifecycle. These services enable sponsors to accelerate development while reducing costs and accessing specialist expertise.
The market encompasses a broad range of activities, including:
- Clinical trial management
- Pre-clinical research
- Regulatory affairs
- Site management
- Data management and biostatistics
- Pharmacovigilance
- Medical writing
- Biometrics
- Real-world evidence studies
- Medical device clinical evaluation
Vietnam offers several competitive advantages for global sponsors. A population of more than 100 million people, increasing disease diversity, expanding hospital networks and a growing number of internationally trained investigators make the country attractive for Phase II, III and IV clinical trials. At the same time, competitive operating costs and improving research capabilities continue to encourage international pharmaceutical companies to include Vietnam within regional development programmes.
Growth in Vietnam's pharmaceutical manufacturing industry is also increasing demand for CRO services. Domestic manufacturers are investing in new drug development, biosimilars and advanced therapeutics while multinational companies continue to expand operations across Southeast Asia. As research pipelines become more complex, outsourcing specialist functions—including clinical operations, regulatory submissions and data management—is becoming an increasingly important strategy.
Technology is transforming the CRO sector worldwide. Artificial intelligence is improving patient recruitment, protocol design and clinical data analysis, while decentralised clinical trials (DCTs), electronic data capture (EDC), remote monitoring and digital patient engagement platforms are enabling faster, more efficient research. These innovations are expected to become increasingly important as Vietnam's clinical research ecosystem continues to mature.
The wider Asia-Pacific region is also experiencing strong momentum. The regional CRO market is projected to grow at more than 8% annually, supported by regulatory modernisation, increased pharmaceutical R&D investment and growing demand for outsourced research services. Vietnam is well positioned to benefit from these trends as sponsors diversify research activities across the region.
Globally, the CRO services market reached US$83.6 billion in 2025 and is forecast to expand to US$169.8 billion by 2034, reflecting sustained investment in drug development, biologics, precision medicine and increasingly complex clinical trials. The outsourcing of research activities continues to be one of the pharmaceutical industry's fastest-growing business models.
Leading global CROs include IQVIA, ICON plc, Parexel, Fortrea, Charles River Laboratories, Medpace, PPD (Thermo Fisher Scientific), Syneos Health, WuXi AppTec and Labcorp Drug Development. These organisations continue to invest in digital clinical trials, AI-enabled research platforms and integrated development services to meet growing global demand.
As Vietnam continues to strengthen its pharmaceutical industry, expand clinical research capacity and attract international investment, the country's CRO sector is expected to play an increasingly important role in the regional life sciences ecosystem. For pharmaceutical companies, biotechnology innovators, medical device manufacturers, technology providers and specialist research service organisations, Vietnam represents one of Southeast Asia's most promising emerging markets for outsourced research and clinical development.
